Tetraphase Pharmaceuticals, Inc.
(NASDAQ : TTPH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
CTLTCatalent, Inc. -2.83%74.732.3%$130.41m
MYOKMyoKardia, Inc. -0.60%98.231.8%$125.78m
BHCBausch Health Cos., Inc. -0.72%19.230.0%$125.36m
HZNPHorizon Therapeutics Plc 1.14%48.126.5%$124.56m
VRXValeant Pharmaceuticals International, Inc. -0.72%19.2314.1%$113.15m
UTHRUnited Therapeutics Corp. 1.00%123.6414.3%$78.66m
PTLAPortola Pharmaceuticals, Inc. -0.06%17.916.5%$75.11m
ARGXargenx SE -2.29%225.950.0%$63.49m
ICPTIntercept Pharmaceuticals, Inc. 2.02%77.9216.8%$63.27m
JAZZJazz Pharmaceuticals Plc -1.01%120.652.4%$56.20m
GWPHGW Pharmaceuticals Plc 0.62%128.136.2%$53.62m
AMRNAmarin Corp. Plc -1.18%6.681.6%$50.61m
AXSMAxsome Therapeutics, Inc. 3.89%77.381.9%$47.82m
PRGOPerrigo Co. Plc 0.74%55.646.8%$44.30m
ICLRICON plc -1.39%162.624.3%$39.28m

Company Profile

Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also engages in the development of product candidate, eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.